Skip to main content

Market Overview

BioSim Pharmaceuticals to Meet with Industry During JP Morgan Healthcare Conference

Share:
SEATTLE--(BUSINESS WIRE)--

Held annually in San Francisco, the JP Morgan Conference, alongside Biotech Showcase and OneMedForum, is one of the largest investment symposia in the healthcare industry. BioSim Pharmaceuticals will be taking advantage of the conference period to meet with potential investors and partners to give exciting news on the progress of their research and development program.

Almost three years into the program, BioSim's flagship product, an ACTH Gel, looks to become the first generic to market. What's more, the company promises to maintain market share by pricing its interchangeable products significantly lower than those of potential generic competitors. Priced at four figures, the ACTH gel is a generic version of the branded drug H.P. ACTHAR®, manufactured by Mallinckrodt Plc (NYSE: MNK). In 2014, Mallinckrodt purchased the previous owner, Questcor Pharmaceuticals (NASDAQ: QCOR), through a tax inversion valued at over 5 billion dollars. In defending their market position, Mallinckrodt last month compared the complexity of ACTHAR® to that of Premarin®. ACTHAR is a biologic drug also known as Corticotropin. Among its several indications, the drug treats infantile spasms and rare autoimmune disorders such as nephrotic syndrome and multiple sclerosis and currently is in clinical trials for ALS (Amyotrophic Lateral Sclerosis).

Over the past few decades, the market for specialty biopharmaceutical products for rare diseases has blossomed. For established companies like Mylan and Par Pharmaceuticals, as well as niche players like Momenta and Endo Pharmaceuticals, the space continues to see rapid growth. BioSim has positioned itself to be a low-cost generic leader in the niche orphan drug market with the goal of helping lower the cost of medicine for America's Healthcare System.

Parties interested in securing a meeting with BioSim, please contact bizdev@BioSimllc.com

About BioSim Pharmaceuticals

BioSim (BioSimllc.com), a Seattle-based pharmaceutical company started in early 2012, is focused on building a portfolio around complex generic drugs for the orphan disease and biologic marketplace. BioSim consists of a team of highly capable individuals with decades of pharmaceutical industry experience all working together to bring products to market that help lower the escalating cost of healthcare.

H.P. ACTHAR® and Premarin® are registered trademarks of their respective owners.

BioSim Pharmaceuticals LLC
Candy Coates, 206-552-0630
press@BioSimllc.com

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com